These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36413739)

  • 21. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
    Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
    Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
    Support Care Cancer; 2006 Jan; 14(1):11-21. PubMed ID: 15999264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
    Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 29. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
    Gopar-Nieto R; Aguilar-Madrid G; Sotelo-Martínez L; Juárez-Pérez CA; Kelly-García J; Argote-Greene L; Ochoa-Vázquez MD; García-Bazán EM; Ramírez-Pérez J; Haro-García L; Jiménez-Ramírez C; Cabello-López A
    Arch Med Res; 2015 Feb; 46(2):107-11. PubMed ID: 25707292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
    Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
    J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
    Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.
    Nakai T; Matsumoto Y; Sasada S; Tanaka M; Tsuchida T; Ohe Y; Motoi N
    Jpn J Clin Oncol; 2019 Jun; 49(6):559-566. PubMed ID: 30882147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
    Mendoza TR; Williams LA; Keating KN; Siegel J; Elbi C; Nowak AK; Hassan R; Cuffel B; Cleeland CS
    J Patient Rep Outcomes; 2019 Jun; 3(1):34. PubMed ID: 31209661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid diagnosis of malignant pleural mesothelioma and its discrimination from lung cancer and benign exudative effusions using blood serum.
    Yonar D; Severcan M; Gurbanov R; Sandal A; Yilmaz U; Emri S; Severcan F
    Biochim Biophys Acta Mol Basis Dis; 2022 Oct; 1868(10):166473. PubMed ID: 35753541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
    Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
    Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
    Pei D; Li Y; Liu X; Yan S; Guo X; Xu X; Guo X
    Oncotarget; 2017 Feb; 8(8):13030-13038. PubMed ID: 28103581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
    Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
    Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.